[1]Parvizi J, Parmar R, Raphael IJ, et al. Proximal deep venous thrombosis and pulmonary embolus following total joint arthroplasty. J Arthroplasty. 2014;29(9):1846-1848.
[2]Januel JM, Chen G, Ruffieux C, et al. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review. JAMA. 2012; 307(3):294-303.
[3]Mont MA, Jacobs JJ. AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg. 2011;19(12):777-778.
[4]Baarslag HJ, van Beek EJ, Koopman MM, et al. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. Ann Intern Med. 2002; 136(12):865-872.
[5]Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. 2009;113(13): 2878-2887.
[6]Cronan JJ. Deep vein thrombosis: imaging diagnosis and related controversies. Ultrasound Clin. 2011;6(4):421-433.
[7]Cosmi B, Palareti G. Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. Thromb Res. 2010;125 Suppl 2:S62-65.
[8]Righini M, Bounameaux H. Clinical relevance of distal deep vein thrombosis. Curr Opin Pulm Med. 2008;14(5):408-413.
[9]Bounameaux H, Miron MJ, Blanchard J, et al. Measurement of plasma D-dimer is not useful in the prediction or diagnosis of postoperative deep vein thrombosis in patients undergoing total knee arthroplasty. Blood Coagul Fibrinolysis. 1998;9(8): 749-752.
[10]Khaira HS, Mann J. Plasma D-dimer measurement in patients with suspected DVT--a means of avoiding unnecessary venography. Eur J Vasc Endovasc Surg. 1998; 15(3): 235-238.
[11]Watanabe H, Madoiwa S, Sekiya H, et al. Predictive blood coagulation markers for early diagnosis of venous thromboembolism after total knee joint replacement. Thromb Res. 2011;128(6):e137-143.
[12]Castro DJ, Pérez-Rodríguez E, Montaner L, et al. Diagnostic value of D dimer in pulmonary embolism and pneumonia. Respiration. 2001;68(4):371-375.
[13]Perrier A. D-dimer for suspected pulmonary embolism: whom should we test? Chest. 2004;125(3):807-809.
[14]Mountain D, Jacobs I, Haig A. The VIDAS D-dimer test for venous thromboembolism: a prospective surveillance study shows maintenance of sensitivity and specificity when used in normal clinical practice. Am J Emerg Med. 2007;25(4): 464-471.
[15]Ho CH. Can very high level of D-dimer exclusively predict the presence of thromboembolic diseases? J Chin Med Assoc. 2011;74(4):151-154.
[16]Konstantinides SV. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(45):3145-3146.
[17]Douma RA, le Gal G, Söhne M, et al. Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts. BMJ. 2010;340:c1475.
[18]O'Donnell J, Tuddenham EG, Manning R, et al. High prevalence of elevated factor Ⅷ levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost. 1997;77(5):825-828.
[19]Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg. 2009;108(5): 1433-1446.
[20]Jenkins PV, Rawley O, Smith OP, et al. Elevated factor Ⅷ levels and risk of venous thrombosis. Br J Haematol. 2012; 157(6):653-663.
[21]Ota S, Yamada N, Ogihara Y, et al. High plasma level of factor Ⅷ: an important risk factor for venous thromboembolism. Circ J. 2011;75(6):1472-1475.
[22]Kraaijenhagen RA, in't Anker PS, Koopman MM, et al. High plasma concentration of factor Ⅷc is a major risk factor for venous thromboembolism. Thromb Haemost. 2000;83(1):5-9.
[23]Tichelaar V, Mulder A, Kluin-Nelemans H, et al. The acute phase reaction explains only a part of initially elevated factor Ⅷ:C levels: a prospective cohort study in patients with venous thrombosis. Thromb Res. 2012;129(2): 183-186.
[24]Soria JM, Almasy L, Souto JC, et al. A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor Ⅷ activity and its relation to thrombosis susceptibility. Blood. 2003;101(1): 163-167.
[25]Viel KR, Machiah DK, Warren DM, et al. A sequence variation scan of the coagulation factor Ⅷ (FⅧ) structural gene and associations with plasma FⅧ activity levels. Blood. 2007; 109(9):3713-3724.
[26]Emmerechts J, Vanassche T, Loyen S, et al. Partial versus complete factor Ⅷ inhibition in a mouse model of venous thrombosis. Thromb Res. 2012;129(4):514-519.
[27]Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4-15.
[28]Ryland JK, Lawrie AS, Mackie IJ, et al. Persistent high factor Ⅷ activity leading to increased thrombin generation - a prospective cohort study. Thromb Res. 2012;129(4):447-452.
[29]Haas FJ, Schutgens RE, Kluft C, et al. A thrombin generation assay may reduce the need for compression ultrasonography for the exclusion of deep venous thrombosis in the elderly. Scand J Clin Lab Invest. 2011;71(1):12-18.
[30]Horan JT, Francis CW. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost. 2001;27(6):657-666.
[31]Caliezi C, Fünfsinn N, Mauron T, et al. Performance of a new fibrin monomer assay to exclude deep vein thrombosis in symptomatic outpatients. Thromb Haemost. 1999;81(1): 50-53.
[32]Dopsaj V, Bogavac-Stanojevic N, Vasic D, et al. Excluding deep venous thrombosis in symptomatic outpatients: is fibrin monomer aid to D-dimer analysis? Blood Coagul Fibrinolysis. 2009;20(7):546-551.
[33]Ley K. The role of selectins in inflammation and disease. Trends Mol Med. 2003;9(6):263-268.
[34]McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost. 2001;86(3):746-756.
[35]Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med. 2004;10(4): 171-178.
[36]Théorêt JF, Yacoub D, Hachem A, et al. P-selectin ligation induces platelet activation and enhances microaggregate and thrombus formation. Thromb Res. 2011;128(3):243-250.
[37]Miszti-Blasius K, Debreceni IB, Felszeghy S, et al. Lack of P-selectin glycoprotein ligand-1 protects mice from thrombosis after collagen/epinephrine challenge. Thromb Res. 2011;127(3): 228-234.
[38]Fijnheer R, Frijns CJ, Korteweg J, et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost. 1997;77(6): 1081-1085.
[39]Zarbock A, Müller H, Kuwano Y, et al. PSGL-1-dependent myeloid leukocyte activation. J Leukoc Biol. 2009;86(5): 1119-1124.
[40]André P, Hartwell D, Hrachovinová I, et al. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A. 2000;97(25):13835-13840.
[41]del Conde I, Nabi F, Tonda R, et al. Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes. Arterioscler Thromb Vasc Biol. 2005; 25(5):1065-1070.
[42]Myers D Jr, Farris D, Hawley A, et al. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. J Surg Res. 2002;108(2):212-221.
[43]Myers DD, Hawley AE, Farris DM, et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg. 2003;38(5):1075-1089.
[44]Rectenwald JE, Myers DD Jr, Hawley AE, et al. D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost. 2005; 94(6):1312-1317.
[45]Blann AD, Noteboom WM, Rosendaal FR. Increased soluble P-selectin levels following deep venous thrombosis: cause or effect? Br J Haematol. 2000;108(1):191-193.
[46]Smith A, Quarmby JW, Collins M, et al. Changes in the levels of soluble adhesion molecules and coagulation factors in patients with deep vein thrombosis. Thromb Haemost. 1999; 82(6):1593-1599.
[47]Shi D, Xu X, Xu Z, et al. P-selectin: an unpredicted factor for deep vein thrombosis after total hip arthroplasty. Biomed Res Int. 2014;2014:783967.
[48]Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol. 2010;30(8): 1672-1678.
[49]Roumen-Klappe EM, den Heijer M, van Uum SH, et al. Inflammatory response in the acute phase of deep vein thrombosis. J Vasc Surg. 2002;35(4):701-706.
[50]Bucek RA, Reiter M, Quehenberger P, et al. C-reactive protein in the diagnosis of deep vein thrombosis. Br J Haematol. 2002;119(2):385-389.
[51]Rabinovich A, Cohen JM, Cushman M, et al. Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome. J Thromb Haemost. 2015;13(3):398-408.
[52]Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 2002;113(8):636-642.
[53]Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost. 2005;94(2):362-365.
[54]Poredos P, Jezovnik MK. In patients with idiopathic venous thrombosis, interleukin-10 is decreased and related to endothelial dysfunction. Heart Vessels. 2011;26(6):596-602.
[55]Downing LJ, Strieter RM, Kadell AM, et al. IL-10 regulates thrombus-induced vein wall inflammation and thrombosis. J Immunol. 1998;161(3):1471-1476.
[56]Enjeti AK, Lincz LF, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology. Semin Thromb Hemost. 2007;33(8):771-779.
[57]Burger D, Schock S, Thompson CS, et al. Microparticles: biomarkers and beyond. Clin Sci (Lond). 2013;124(7): 423-441.
[58]Noci MV, Ramírez R, Lluch M, et al. Changes in endothelial microparticles and endothelial progenitor cells in obese patients in response to surgical stress. J Bone Joint Surg Am. 2015;97(5):353-358.
[59]Morel O, Toti F, Hugel B, et al. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol. 2006;26(12):2594-2604.
[60]Ramacciotti E, Hawley AE, Farris DM, et al. Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis. Thromb Haemost. 2009;101(4):748-754.
[61]Stoffel N, Rysler C, Buser A, et al. Leukocyte count and risk of thrombosis in patients undergoing haematopoietic stem cell transplantation or intensive chemotherapy. Thromb Haemost. 2010;103(6):1228-1232.
[62]Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645-1651.
[63]Hou H, Ge Z, Ying P, et al. Biomarkers of deep venous thrombosis. J Thromb Thrombolysis. 2012;34(3):335-346.
[64]Qin J, Liang H, Shi D, et al. A panel of microRNAs as a new biomarkers for the detection of deep vein thrombosis. J Thromb Thrombolysis. 2015;39(2):215-221.
[65]Geersing GJ, Zuithoff NP, Kearon C, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ. 2014; 348:g1340.
[66]Ramacciotti E, Blackburn S, Hawley AE, et al. Evaluation of soluble P-selectin as a marker for the diagnosis of deep venous thrombosis. Clin Appl Thromb Hemost. 2011;17(4): 425-431. |